Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.

Regeneron - R3767-ONC-22122

Study Phase: Phase III - Drug

Condition(s): Unresectable or metastatic melanoma
A Phase 3 Study Of Fixed Dose Combinations Of Fianlimab And Cemiplimab Versus Relatlimab And Nivolumab In Participants With Unresectable Or Metastatic Melanoma

ClinicalTrials.gov NCT ID: NCT06246916

You can view the full clinical description on ClinicalTrials.gov.

View Full Description
profile_amy-grossman

Amy Grossman, RN

Primary Contact - Study Coordinator

484-658-1788
amy.grossman@sluhn.org

profile_melissa-wilson

Melissa A. Wilson, MD, PhD

Physician - Principal Investigator

U of Kentucky - UKY-MCC-20-MEL-11-PMC

Study Phase: Phase I - Drug

Condition(s): BRAF mutated metastatic melanoma
A Phase I Study of Nilotinib in Combination with Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma after Progression on BRAF/MEK Inhibition

ClinicalTrials.gov NCT ID: NCT04903119

You can view the full clinical description on ClinicalTrials.gov.

View Full Description
profile_amy-grossman

Amy Grossman, RN

Primary Contact - Study Coordinator

484-658-1788
amy.grossman@sluhn.org

profile_melissa-wilson

Melissa A. Wilson, MD, PhD

Physician - Principal Investigator

To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.

Cancer Ribbon

Transforming lives through philanthropy

Supporting clinical trials and research can help us create a future where advanced health care is accessible and equitable for everyone. Together, we can transform lives and improve health care for generations to come.

Donate today